By the physicians of Amanecia Health | Updated April 27, 2026
Related: Read our follow-up on the NPR report on peptide restrictions and what it means for patients.
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. publicly addressed FDA action on a group of peptide substances that had been on the FDA’s Category 2 restricted compounding list. The companies that originally nominated those peptides for that list have since withdrawn their nominations, and the peptides come off Category 2 effective April 23, 2026. The FDA’s Pharmacy Compounding Advisory Committee will review whether to officially clear any of them for compounding at its July 23-24, 2026 meeting.
For patients who rely on peptide therapy for recovery, immune support, metabolic health, and longevity, this is significant news. But it also comes with an important caveat that isn’t getting enough attention: this regulatory change is not the same as FDA approval, and how you access these therapies matters just as much as whether you can.
What Changed, and What Didn’t
In late 2023, the FDA moved 19 widely used peptides to its Category 2 list, effectively banning compounding pharmacies from preparing them. The stated rationale was safety concerns, though many clinicians and compounding pharmacy groups argued the agency overstepped, noting that no specific safety signal justified the restriction for most of the affected peptides.
Removal from Category 2 is a step, not a clearance. The FDA still has specific criteria a substance must meet to be eligible for compounding, and the Pharmacy Compounding Advisory Committee’s July 2026 review will determine whether any of these peptides will be officially cleared. Even where compounding becomes permitted, it does not mean these peptides are FDA-approved drugs. They remain prescription therapeutics used under physician supervision, with proper dosing and ongoing monitoring.
Among the peptides removed from the Category 2 list and now under PCAC review:
-
- BPC-157 : studied for tissue repair, gut healing, and reducing inflammation
-
- Thymosin Alpha-1 : an immune-modulating peptide with applications in infectious disease and oncology support
-
- TB-500 (Thymosin Beta-4) : studied for muscle repair, flexibility, and recovery
-
- CJC-1295 and Ipamorelin : growth hormone-releasing peptides that support sleep, metabolism, and lean muscle
-
- AOD-9604 : a peptide fragment studied for fat metabolism
-
- Selank and Semax : neuropeptides studied for cognitive function and anxiety
-
- KPV : an anti-inflammatory peptide with potential gut health applications
-
- MOTS-C : a mitochondrial peptide studied for metabolic regulation
-
- GHK-Cu : a copper peptide studied for wound healing and regeneration
Why This Matters, and Why It’s Not a Free-for-All
The Category 2 restrictions didn’t eliminate demand for these peptides. They pushed patients toward unregulated gray-market sources: “research use only” vendors with no pharmaceutical oversight, no quality control, and no guarantee of purity or correct dosing. Kennedy himself acknowledged this directly, stating that the restrictions “created the gray market.”
Removal from Category 2 is a step toward potentially restoring safe, regulated access, depending on what the PCAC review concludes in July. Either way, safe access depends on two things: the quality of the compounding pharmacy preparing the peptide, and the physician overseeing the therapy.
This is where the difference between buying peptides online and receiving peptide therapy under physician supervision becomes critical.
How Amanecia Health Approaches Peptide Therapy
At Amanecia Health, peptide therapy is not a product we sell. It’s a treatment we prescribe, monitor, and adjust based on each patient’s individual health profile and goals. Every peptide protocol is designed and overseen by a board-certified Emergency Medicine physician.
Our approach includes:
-
- Clinical evaluation before prescribing : We assess your health history, current medications, lab results, and treatment goals before recommending any peptide therapy.
-
- Sourcing from licensed, compliant pharmacies : All peptides are sourced from FDA-registered, U.S.-based compounding pharmacies that comply with USP 797 and 795 standards.
-
- Ongoing monitoring and dose adjustment : Peptide therapy isn’t one-size-fits-all. We monitor your response, adjust dosing, and ensure your protocol evolves with your health.
-
- Integration with your broader care : Peptide therapy works best as part of a comprehensive wellness plan. Our physicians coordinate it alongside other treatments and health priorities.
What Patients Should Know Right Now
The FDA’s formal action takes effect April 23, 2026, with the PCAC review of these substances scheduled for July 23-24, 2026. In the meantime:
-
- Don’t rush to gray-market sources. Working with a physician and a licensed compounding pharmacy provides quality control and oversight that gray-market sources cannot.
- Work with a physician, not an influencer. Peptide dosing, timing, and combination protocols require medical expertise. Social media is full of peptide advice from people without clinical training.
- Ask about sourcing. Not all compounding pharmacies are equal. Ask your provider where their peptides come from and whether the pharmacy holds current USP compliance.
- Understand what “not FDA-approved” means. Even when peptides become eligible for compounding, they have not gone through the clinical trial process required for FDA drug approval. They remain prescription therapeutics used under physician discretion.
The Bottom Line
The shifting regulatory picture is potentially good news for patients who benefit from peptide therapies, depending on PCAC’s July decision. But the biggest risk was never the peptides themselves. It was unregulated access without physician oversight, and that risk doesn’t go away no matter what the regulatory status becomes.
If you’re interested in peptide therapy for recovery, immune support, metabolic health, or longevity, the right move is to work with a physician who can evaluate whether it’s appropriate for you, prescribe the correct protocol, and monitor your progress.
Amanecia Health offers physician-led peptide therapy delivered in your home or via telemedicine. Our board-certified Emergency Medicine physicians are available to discuss whether peptide therapy is right for your health goals.
Amanecia Health provides concierge medicine services including peptide therapy, weight loss medications, hormone replacement therapy, in-home urgent care, and telemedicine visits across Austin, Houston, Dallas–Fort Worth, and Coastal Virginia. All care is delivered by board-certified Emergency Medicine physicians.
Note: Compounded peptides are not FDA-approved drugs. They are prepared by licensed compounding pharmacies under physician prescription and have not been evaluated through clinical trials for safety, efficacy, or therapeutic equivalence to any FDA-approved medications. This content is for informational purposes and does not constitute medical advice.